

Revista Española de Cirugía Ortopédica y Traumatología



www.elsevier.es/rot

ORIGINAL

[Translated article] Risk factors for complications in total hip arthroplasty



L.A. Hoyos-Velasco^{a,*}, J.C. Palacio^a, W.P. Stangl^a, C.L. Chacón-Castillo^b, V. Palacio-Aragón^b, J.P. Pulgarín^b

Received 27 March 2023; accepted 9 June 2024 Available online 14 February 2025

KEYWORDS

Hip; Total hip arthroplasty; Risk factors; Postoperative complications; Hip prosthesis

Abstract

Introduction and objective: Hip arthroplasty represents a significant advancement in the treatment of refractory chronic joint pain, improving quality of life and functionality. The objective of this study is to identify the risk factors associated with local and systemic complications in patients treated with total hip arthroplasty.

Methods: Observational, analytical, retrospective cohort study, which included 304 participants treated with total hip replacement. Comparison of variables between two groups was performed; 38 participants in the group with complications and 266 participants in the group without complications.

Results: The mean age in the complication group was 66 years (SD 18.7) and in the uncomplicated group it was 67.1 years (SD 15.1) (p 0.686). Female sex was observed in 73.3% of the group with complications and 65% in the group without complications (p 0.292). Risk factors were: hip fracture as an indication for arthroplasty RR 1.33 [95% CI 1.004; 1.775 p 0.047], coronary heart disease RR 1.31 [95% CI 1.067; 1.616 p 0.010] and surgical bleeding equal to or greater than 400 cc RR 1.11 [95% CI 1.012; 1.218 p 0.028].

Conclusions: The risk factors for complications in total hip arthroplasty were: hip fracture as the indication for arthroplasty, coronary artery disease, and surgical bleeding equal to or greater than 400 cc.

© 2024 SECOT. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

E-mail address: lhoyosv@unal.edu.co (L.A. Hoyos-Velasco).

a Servicio de Ortopedia y Traumatología, Grupo de Cirugía Articular de Cadera y Rodilla, Clínica Imbanaco, Cali, Colombia

^b Medicina General, Servicio de Ortopedia y Traumatología, Clínica Imbanaco, Cali, Colombia

DOI of original article: https://doi.org/10.1016/j.recot.2024.06.006

^{*} Corresponding author.

PALABRAS CLAVE

Cadera; Artroplastia total de cadera; Factores de riesgo; Complicaciones postoperatorias; Prótesis de cadera

Factores de riesgo para complicaciones en artroplastia total de cadera

Resumen

Introducción y objetivo: La artroplastia de cadera es un gran avance para el tratamiento del dolor articular crónico refractario, que mejora la calidad de vida y la funcionalidad. El objetivo de este estudio es identificar los factores de riesgo asociados a complicaciones locales y sistémicas en pacientes tratados con artroplastia total de cadera.

Métodos: Estudio observacional, analítico, de cohorte retrospectiva, que incluyó a 304 participantes tratados con reemplazo total de cadera. Se realizó la comparación de variables entre dos grupos: 38 participantes en el grupo de complicaciones y 266 participantes en el grupo sin complicaciones.

Resultados: La media de edad en el grupo de complicación fue de 66 años (DE 18,7) y en el grupo sin complicaciones fue de 67,1 años (DE 15,1) (p=0,686). El sexo femenino se observó en el grupo de complicaciones en el 73,3%, y en el grupo sin complicaciones en el 65% (p=0,292). Los factores de riesgo fueron: fractura de cadera como indicación de la artroplastia RR 1,33 [IC 95% 1,004;1,775 p=0,047], enfermedad coronaria RR 1,31 [IC 95% 1,067;1,616 p=0,010] y sangrado quirúrgico igual o mayor a 400 cc RR 1,11 [IC 95% 1,012;1,218 p=0,028].

Conclusiones: Los factores de riesgo para complicaciones en artroplastia total de cadera fueron: fractura de cadera como indicación de la artroplastia, enfermedad coronaria y sangrado quirúrgico igual o mayor a 400 cc.

© 2024 SECOT. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (http://creativecommons.org/licencias/by-nc-nd/4.0/).

Introduction

Osteoarthrosis of the hip joint is a complex chronic disease characterised by degeneration of the articular cartilage and thickening of the subchondral bone. This condition impacts joint function, is painful, and adversely affects the patient's quality of life. Primary arthroplasty of the hip is the treatment of choice to address advanced osteoarthrosis of the hip, given that it improves function and provides effective pain relief.^{2,3} While it is a safe procedure, total hip replacement does not come without its complications and can entail associated infection, instability, and loosening or wear of the prosthesis, which, in some cases, may warrant revision surgery.^{2,4,5} With nearly 650,000 procedures performed each year in the United States and a projected increase by up to 70% in the number of surgeries by the year 2030, studying the potential complications and various interventions to minimise risk is of paramount importance. 6,7 Sociodemographic factors, comorbidities, surgery-specific factors, as well as the use of certain medications have been found to correlate with the incidence of complications in total hip arthroplasty⁸; nevertheless, definitive conclusions regarding the factors associated with worse surgical outcomes have yet to be reached. This study seeks to identify the factors associated with worse surgical outcomes in total hip arthroplasty, in addition to identifying risk factors associated with complications in patients undergoing this type of surgery.

Methods

After the approval of the ethics and research committee of the Imbanaco Clinic (referral hospital in the city of Cali, Colombia) registered under CEI-000002-Protocol CEI-660, a retrospective observational cohort study was conducted; the sample size for cohort studies was calculated using the Epidat software programme, version 4.2 (Servicio de Epidemioloxía de la Dirección Xeral de Saúde Pública de la Consellería de Sanidade [Expidemiology Service of the Department of Health], Xunta de Galicia [the Regional Government of Galicia], with the support of the Pan American Health Organization [PAHO-WHO] and the CES University of Colombia). The parameters were: risk in those exposed 7%, 10 95% confidence level, 80% power, application of Yates correction for a minimum sample size of 279 patients, nonprobabilistic convenience sampling. The inclusion criteria consisted of patients aged 18 years or older, with a minimum follow-up of six months, treated with total hip arthroplasty by the Knee and Hip Joint Surgery Group between the years 2010 and 2022. The exclusion criteria included incomplete medical records and any other surgical treatment during the same operation time.

The database was recorded in the 2019 version of Excel® (Microsoft Corporation, Redmond, Washington, United States) and subsequently analysed using the SPSS® software package, version 28 (IBM, Armonk, New York, United States). The univariate analysis was carried out by means of descriptive statistics, determining absolute and relative frequencies in the categorical variables; for the numerical variables, measures of central tendency and dispersion were ascertained. The bivariate analysis to determine associations between the different categorical variables was performed using Pearson's χ^2 test, which yielded the p value (significant <0.05) and the RR (relative risk) with its 95% confidence interval. Likewise, the multivariate analysis relied on the Poisson generalised linear regression model; the variables that displayed an association in the bivariate

analysis and with a theoretical representative value were included in the model.

For the present study, the dependent variable was defined as the overall incidence of complications, defined as any local (superficial or deep infection of the surgical site, dislocation of the prosthesis, periprosthetic fracture, peripheral nerve injury, loosening of the prosthesis, and shortening of the limb) or systemic complication directly related to the postoperative period (severe anaemia requiring transfusion, death, pulmonary embolism, ventricular tachycardia, urinary tract infection, or pneumonia). The independent variables were: age 70 years or older, sex, arterial hypertension, diabetes mellitus, malnutrition, normal weight, overweight (BMI between 25 and 29.9), obesity (BMI ≥30), heart failure, coronary heart disease, cardiac arrhythmia, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), Parkinson's disease, hypothyroidism, rheumatoid arthritis, osteoporosis, Alzheimer's disease/dementia, anaemia, cancer, coxarthrosis, hip dysplasia, hip fracture, avascular necrosis, right lateral, posterolateral approach, anterolateral approach, total prosthesis, bipolar prosthesis, Exactech® prosthesis (Exactech, Inc., Gainesville, Florida, USA) (standard stem, uncemented), Johnson® prosthesis (DePuy Synthes, Warsaw, Indiana. Country: USA) (standard stem, uncemented), Link® prosthesis (Waldemar Link GmbH & Co. KG, Hamburg, Germany) (standard stem, uncemented) (standard stem, uncemented), Johnson® prosthesis (DePuy Synthes, Warsaw, Indiana. Country: USA) (standard stem, uncemented), Link® prosthesis (Waldemar Link GmbH & Co. KG, Hamburg, Germany) (standard stem, uncemented), Corin® prosthesis (Corin Group, Cirencester, Gloucestershire, United Kingdom) (standard stem, uncemented), Smith and Nephew® prosthesis (Smith & Nephew plc, London, United Kingdom) (standard stem, uncemented), Stryker® prosthesis (Stryker Corporation, Kalamazoo, Michigan, United States) (standard stem, uncemented), surgical time equal to or greater than 130 min, intraoperative bleeding equal to or exceeding 130 min, and thromboprophylaxis. All outcomes were assessed up to 12 months from the date of the surgical procedure.

Inclusion and exclusion criteria were used to control for selection bias; variables were collected from medical records without prior knowledge of which patients did or did not develop any complication, and a Poisson regression model was used to control for confounding bias.

Results

The institution's database included 310 patients; six were ruled out because they were miscoded and corresponded to knee joint replacements.

Univariate analysis

The total sample comprised 304 subjects, most of whom were female (66.1%). The youngest participant was 18 years old and the oldest one was 96 years old; the mean age was 67 years (SD 15.7 years). More than half (54.9%) had a history of arterial hypertension; 42.8% were overweight; 17.8% were obese; 17.8% had hypothyroidism; 11.2% had

Variable	Result			
	304 (100%)			
Arterial hypertension	167 (54.9%)			
Nutritional status				
Malnourished	10 (3.3%)			
Normal weight	110 (36.2%)			
Overweight	130 (42.8%)			
Obesity	54 (17.8%)			
Hypothyroidism	54 (17.8%)			
Diabetes mellitus	34 (11.2%)			
Coronary heart disease	31 (10.2%)			
Cancer	21 (6.9%)			
Chronic obstructive pulmonary disease	18 (5.9%)			
Alzheimer's disease/dementia	17 (5.6%)			
Congestive heart failure	16 (5.3%)			
Chronic kidney disease	12 (3.9%)			
Osteoporosis	12 (3.9%)			
Rheumatoid arthritis	10 (3.3%)			
Parkinson's disease	7 (2.3%)			
Cardiac arrhythmia	5 (1.6%)			
Cerebrovascular disease	4 (1.3%)			
Anaemia	4 (1.3%)			

diabetes mellitus, and 10.2% had coronary heart disease (Table 1). The number one indication for total hip arthroplasty was coxarthrosis (74.3%), followed by hip fracture (19.7%), and avascular necrosis (3.2%) (Fig. 1). As for the characteristics of the surgery itself, the side most often treated was the right hip (54.9%); the most widely used approach was posterolateral (96.4%), followed by anterolateral (2.3%). The most extensively implanted prostheses were complete, accounting for 88.8%, and bipolar in 11.2% of the cases. The brands of implants were Exactech® 74.7%, Link® 14.5%, Johnson® 6.3%, Stryker® 2.3%, Corin® 1.6%, and others 0.7%. Of the people who underwent total hip arthroplasty, 97.7% received antithrombotic prophylaxis; the mean operative time was 137 min (SD 64.4); the mean intraoperative bleeding was 375 cc (SD 193), and the mean number days of hospital stay was four (SD 4.7).

The overall incidence of complications was 12.5% (including all types of complications, regardless of the degree of severity). Each complication was categorised considering the four groups as put forth by Belmont et al. 11 and on the basis of the grade of severity; i.e., major systemic (death, anaemia requiring transfusion, pulmonary thromboembolism [PTE], and ventricular tachycardia), minor systemic (pneumonia and urinary tract infection [UTI]), major local (periprosthetic fracture, prosthesis dislocation, deep surgical site infection, and peripheral nerve injury), and minor local (superficial surgical site infection and limb shortening). This yielded an incidence of major systemic complications of 3%, minor systemic complications of 1.3%, major local complications of 7.2%, and minor local complications of 2.3%.

Table 2 outlines the incidence rate of complications in detail. Both prosthesis dislocation and operative site infection were present with an incidence of 2%, followed by




Figure 1 Indication for total arthroplasty of the hip. Source: Drafted by the authors.

 Table 2
 Incidence of complications in total hip replacement surgery

Complication	Incidence 304 (100%
	304 (100%)
Major systemic	F (4 (0/)
Severe anaemia	5 (1.6%)
Death	4 (1.3%)
Pulmonary embolism	1 (0.3%)
Ventricular tachycardia	1 (0.3%)
Minor systemic	
Urinary tract infection	2 (0.7%)
Pneumonia	2 (0.7%)
Major local	
Dislocation of implant	6 (2%)
Deep SSI	5 (1.6%)
Periprostheic fracture	4 (1.3%)
Peripheral nerve injury	2 (0.7%)
Aseptic loosening	2 (0.7%)
	2 (0.770)
Minor local	
Limb shortening	1 (0.3%)
Superficial SSI	6 (2%)

severe anaemia and deep operative site infection, each displaying an incidence of 1.6%.

As for the need for revision surgery, 4.6% of the participants (14 of 304 patients) required revision. The reasons cited for revision were: dislocation of the prosthesis that

could not be corrected by closed reduction in 35.7% of cases (5 of 14 subjects), deep infection of the operative site in 35.7% of patients (5 of 14 participants), aseptic loosening in 14.3% of cases (2 of 14 patients), and periprosthetic fracture in 14.3% of subjects (2 of 14 individuals).

Bivariate analysis

Variables were compared between two groups: 38 participants in the complication group and 266 individuals in the uncomplicated group. The mean age in the group of total hip arthroplasty patients with complications was 66 years (SD 18.7) and in the group without complications was 67.1 years (SD 15.1), with no significant statistical difference (p=0.686) in this regard. In the group with complications, 73.3% were female, while in the group without complications, 65% were female, again displaying no statistically significant difference (p = 0.292). Thus, it was concluded that the groups were homogeneous when it came to the variables of both sex and age. The risk factors for complications in total hip arthroplasty in order of strength of association (highest to lowest) were: coronary heart disease RR 3.1 (95% CI 1.6; 5.8 p = 0.001), Alzheimer's disease/dementia RR 2.5 (95% CI 1.1; 5.7 p = 0.030), hip fracture as an indication for arthroplasty RR 2.1 (95% CI 1.1; 3.8 p = 0.017), and surgical bleeding equal to or greater than 400 cc RR 1.9 (95% CI 1.07; 3.53 p = 0.026) (Table 3).

Multivariate analysis

Given that the study sample consisted of a cohort with determination of cumulative incidence and calculation of

Variable	Complications (38)	No complications (266)	RR	95% CI	p value
Arterial hypertension	23	144	1.2	0.6; 2.6	0.459
Diabetes mellitus	4	30	0.9	0.3; 2.4	0.891
Malnutrition	2	8	1.6	0.4; 5.8	0.466
Normal weight	15	95	1.1	0.6; 2.1	0.652
Overweight	12	118	0.6	0.3; 1.1	0.136
Obesity	9	45	1.4	0.7; 2.8	0.307
Congestive heart failure	4	12	2.1	0.8; 5.2	0.120
Coronary heart disease	10	21	3.1	1.6; 5.8	0.001
Cardiac arrhythmia	1	4	1.6	0.2; 9.5	0.609
Cerebrovascular disease	1	3	2.0	0.3; 11.3	0.447
Chronic kidney disease	3	9	2.0	0.7; 5.8	0.182
COPD	4	14	1.8	0.7; 4.6	0.198
Parkinson's disease	1	6	1.1	0.1; 7.2	0.885
Hypothyroidism	6	48	0.8	0.3; 1.9	0.734
Rheumatoid arthritis	2	8	1.6	0.4; 5.8	0.466
Osteoporosis	1	11	0.6	0.0; 4.3	0.656
Alzheimer's disease/dementia	5	12	2.5	1.1; 5.7	0.030
Anaemia	1	3	2.0	0.3; 11.3	0.447
Cancer	1	20	0.3	0.0; 2.5	0.266
Coxarthrorsis	24	202	0.5	0.3; 1.0	0.091
Dysplasia of the hip	0	8	-	-	0.279
Hip fracture	13	47	2.1	1.1; 3.8	0.017
Avascular necrosis	1	9	0.7	0.1; 5.2	0.808
Right side	23	144	1.2	0.6; 2.3	0.459
Posterolateral approach	36	257	0.6	0.1; 2.4	0.562
Anterolateral approach	1	6	1.1	0.1; 7.2	0.885
Total prosthesis	31	239	0.5	0.2; 1.1	0.130
Bipolar prosthesis	7	27	1.7	0.8; 3.7	0.130
Exactech prosthesis	30	197	1.2	0.6; 2.6	0.517
Johnson prosthesis	0	19	-	-	0.089
Link prosthesis	7	37	1.3	0.6; 2.8	0.460
Corin prosthesis	0	5	-	-	0.394
Smith prosthesis	0	1	-	-	0.705
Stryker prosthesis	0	7	-	-	0.312
Operative time 130 min or more	20	143	0.9	0.5; 1.7	0.896
Intraoperative bleeding 400 cc or more	21	97	1.9	1.07; 3.53	0.026
Antithrombotic prophylaxis	37	260	0.8	0.1; 5.4	0.885

COPD: chronic obstructive pulmonary disease.

In italics, factors that exhibited a statistically significant association.

Source: Drafted by the authors.

relative risk, the Poisson regression model was used (categorical dependent variable, corresponding to the overall incidence of complications), all the variables that were analysed in the bivariate analysis were included (both those that were statistically significant as well as the variables with a theoretical representative value), and the model was accepted because the incidence deviation/degrees of freedom is 0.066 (<1). The factors that were associated as risk factors for complications in total hip arthroplasty were: hip fracture as an indication for total arthroplasty, coronary artery disease, and surgical bleeding equivalent to or in excess of 400 cc. The use of Exactech®, Johnson®, Corin®, and Stryker® prostheses was a protective factor. All of these implants were standard uncemented stems (Table 4).

Discussion

Revision hip replacement entails an increased risk of complications, risk of bleeding, longer hospital stays, and higher financial costs for health care systems. ¹² In the United States, revision rates for arthroplasties of the hip have been reported to be as high as 17.5% of cases, while in Europe these rates are as low as 6.4% after five years of follow-up. ¹³ In the current study, the revision rate was found to be 4.6%. Paez et al. reported a lower revision rate following total hip replacement, with an incidence of 2.7%. ¹⁴ Dislocation of the hip prosthesis is the number one cause leading to revision in the United States, raising economic costs by 300%. ¹⁵ The dislocation rate in this research work was 2%, which is

Variable	Adjusted RR 0.998	95% CI	95% CI	p value
		Lower limit	Upper limit	
Age 70 years or older		0.910	1.096	0.971
Being male	1.062	0.972	1.162	0.184
Arterial hypertension	0.978	0.890	1.075	0.646
Diabetes mellitus	0.943	0.818	1.087	0.417
Malnutrition	1.031	0.799	1.331	0.812
Normal weight	1.003	0.884	1.138	0.962
Overweight	0.954	0.846	1.075	0.440
Obesity	1	-	-	-
Congestive heart failure	0.909	0.700	1.180	0.472
Coronary heart disease	1.313	1.067	1.616	0.010
Cardiac arrhythmia	0.916	0.641	1.308	0.628
Cerebrovascular disease	1.064	0.746	1.519	0.732
Chronic kidney disease	1.011	0.811	1.261	0.920
COPD	1.142	0.955	1.366	0.145
Parkinson's disease	0.918	0.690	1.221	0.556
Hypothyroidism	0.964	0.862	1.078	0.521
Rheumatoid arthritis	1.020	0.813	1.281	0.862
Osteoporosis	0.891	0.709	1.118	0.318
Alzheimer's disease/dementia	1.118	0.918	1.362	0.267
Anaemia	1.094	0.756	1.583	0.634
Cancer	0.869	0.732	1.032	0.110
Coxarthrorsis	1.096	0.850	1.413	0.482
Dysplasia of the hip	1.031	0.708	1.501	0.875
Hip fracture	1.335	1.004	1.775	0.047
Avascular necrosis	1	-	_	_
Right side	1.011	0.929	1.101	0.799
Posterolateral approach	0.828	0.584	1.175	0.291
Anterolateral approach	0.789	0.483	1.288	0.343
Total prosthesis	1.138	0.955	1.356	0.150
Bipolar prosthesis	1	-	_	-
Exactech prosthesis	0.554	0.316	0.971	0.039
Johnson prosthesis	0.447	0.246	0.815	0.009
Link prosthesis	0.575	0.323	1.025	0.061
Corin prosthesis	0.417	0.221	0.787	0.007
Smith prosthesis	0.512	0.192	1.367	0.182
Stryker prosthesis	0.474	0.250	0.898	0.022
Operative time 130 min or more	0.980	0.892	1.077	0.670
Intraoperative bleeding 400 cc or more	1.110	1.012	1.218	0.028
Antithrombotic prophylaxis	1.006	0.736	1.375	0.971

COPD: chronic obstructive pulmonary disease.

In italics, factors that exhibited a statistically significant association (p value of less than 0.05).

Source: Drafted by the authors.

compatible with data reported in the literature, where an incidence between 0.2% and 5% has been documented.¹⁶

Periprosthetic infection is a major complication of total hip arthroplasty, ¹⁷ which results in multiple revision surgeries and long-term antibiotic treatment, adversely affecting the patient; increasing periods of immobility, the number of readmissions to the emergency department, and compromising quality of life. ¹⁸ According to Franceschini et al., deep infection is associated with increased morbidity and has an incidence rate of approximately 2%¹⁹; a similar incidence of 1.6% was identified in the present study. Meanwhile, Papagrigorakis et al. reported that periprosthetic fracture was noted in 14% of the people treated with

total hip arthroplasty and osteoporosis, which translates into loss of function, as well as increased pain and morbidity and mortality. Contrary to their results, our study identified an incidence of periprosthetic fracture of 1.3%; however, participants were not stratified on the basis of the presence or absence of osteoporosis, which may explain the discrepancies. Peripheral nerve damage is a rare complication of hip replacement surgery. In their study, Hasija et al. reported an incidence of 0.6% to 3.7%, which is in line with the incidence of peripheral nerve damage found in the present study, which was 0.7%. If we look at the study by Zeng et al., which included 210,450 participants treated with total hip replacement, a mortality rate of between 2.6 and 2.9% was

observed in the first 30 days following surgery²²; their registry displays a higher mortality rate compared to the results of this research, in which the mortality rate was found to be 1.3%.

Coronary heart disease is known to be a risk factor that is conducive to worse operative outcomes in orthopaedic surgery²³; specifically in the case of hip arthroplasty, cardiac disease is associated with longer hospital stays, increased readmission rates, and higher mortality, 24,25 In this study. coronary heart disease was identified as a risk factor for complications in total hip arthroplasty; similar results were reported by Edwards et al. who also found heart disease to be a risk factor for complications following hip arthroplasty.²³ A systematic review of the literature published by Stibolt et al. documented an increased risk of complications among patients with hip fracture who had undergone hip arthroplasty.²⁶ This corroborates the results of the present research, in which hip fracture as an indication for total arthroplasty was demonstrated to be a risk factor for complications. Significant blood loss during total hip replacement can increase the rate of blood transfusion, 27 which negatively impacts surgical outcomes and increases the incidence of complications.²⁸ Surgical bleeding equal to or greater than 400 cc was documented in this work to be another risk factor for complications in replacement surgery.

Conclusion

The risk factors for complications in total hip replacement surgery were as follows: hip fracture as the indication for the total arthroplasty, coronary heart disease, and intraoperative bleeding with a loss of 400 cc or more.

Level of evidence

Level of evidence II.

Ethical considerations

This study was conducted in accordance with the ethical standards recognised by the Declaration of Helsinki and Resolution 008430 dated 1993 and has received the approval of the Institution's Ethics Committee. Informed consent was not required given that the research was retrospective in nature and data were obtained from clinical records.

Funding

This research has not received any specific grants from any public or commercial sector or from any non-profit organisations.

Conflicts of interest

The authors have no conflict of interests to declare.

References

- Torini AP, Barsotti CE, Andrade RM, Nali LHDS, Ribeiro AP. Effect
 of total hip arthroplasty with ceramic acetabular component
 on clinical radiographic and functional parameters in older
 patients with hip osteoarthritis: two-year follow-up. J Clin Med.
 2023;12:670, http://dx.doi.org/10.3390/jcm12020670.
- Patel I, Nham F, Zalikha AK, El-Othmani MM. Epidemiology of total hip arthroplasty: demographics, comorbidities and outcomes. Arthroplasty. 2023;5:2, http://dx.doi.org/10.1186/s42836-022-00156-1.
- Lung BE, Donnelly M, Callan K, McLellan M, Amirhekmat A, McMaster WC, et al. Preoperative malnutrition and metabolic markers may predict periprosthetic fractures in total hip arthroplasty. Arthroplast Today. 2023;19:101093, http://dx.doi.org/10.1016/j.artd.2022.101093.
- Hung CC, Chen KH, Chang CW, Chen YC, Tai TW. Salvage total hip arthroplasty after failed internal fixation for proximal femur and acetabular fractures. J Orthop Surg Res. 2023;18:45, http://dx.doi.org/10.1186/s13018-023-03519-9.
- Bäcker HC, Wu CH, Kienzle A, Perka C, Gwinner C. Mechanical failure of total hip arthroplasties and associated risk factors. Arch Orthop Trauma Surg. 2023;143:1061–9.
- Pathak N, Bovonratwet P, Purtill JJ, Bernstein JA, Golden M, Grauer JN, et al. Incidence, risk factors, and subsequent complications of postoperative hematomas requiring reoperation after primary total hip arthroplasty. Arthroplast Today. 2022;19:101015, http://dx.doi.org/10.1016/j.artd.2022.08.008.
- Cieremans D, Shah A, Slover J, Schwarzkopf R, Meftah M. Trends in complications and outcomes in patients aged 65 years and younger undergoing total hip arthroplasty: data from the American Joint Replacement Registry. J Am Acad Orthop Surg Glob Res Rev. 2023;7:e22.00256, http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00256.
- Sweerts L, Dekkers PW, van der Wees PJ, van Susante JLC, de Jong LD, Hoogeboom TJ, et al. External validation of prediction models for surgical complications in people considering total hip or knee arthroplasty was successful for delirium but not for surgical site infection, postoperative bleeding, and nerve damage: a retrospective cohort study. J Pers Med. 2023;13:277, http://dx.doi.org/10.3390/jpm13020277.
- Li G, Yu F, Liu S, Weng J, Qi T, Qin H, et al. Patient characteristics and procedural variables are associated with length of stay and hospital cost among unilateral primary total hip arthroplasty patients: a single-center retrospective cohort study. BMC Musculoskelet Disord. 2023;24:6, http://dx.doi.org/10.1186/s12891-022-06107-w.
- Cushner F, Agnelli G, FitzGerald G, Warwick D. Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010;39 Suppl.:22–8.
- Belmont PJ Jr, Goodman GP, Hamilton W, Waterman BR, Bader JO, Schoenfeld AJ. Morbidity and mortality in the thirty-day period following total hip arthroplasty: risk factors and incidence. J Arthroplasty. 2014;29:2025–30, http://dx.doi.org/10.1016/j.arth.2014.05.015.
- Mahadevan D, Challand C, Keenan J. Revision total hip replacement: predictors of blood loss, transfusion requirements, and length of hospitalisation. J Orthop Traumatol. 2010;11:159–65, http://dx.doi.org/10.1007/s10195-010-0105-z.
- Escallón GR, Nossa JM, Ojeda RR, Osuna JN, Segura
 Revisión de artroplastia total de cadera en el Hospital de San José y el Hospital Infantil Universitario

- de San José (2009-2012): frecuencia de la reintervención y la mortalidad. Rev Col Or Tra. 2017;31:27-33, http://dx.doi.org/10.1016/j.rccot.2017.01.001.
- Páez GR, Nossa JM, Pesantez R. Complicaciones tempranas en la artroplastía total primaria de la cadera. Rev Col Ort Tra. 2006:21:43-9.
- 15. Rowan FE, Benjamin В, **Pietrak** JR, Haddad Prevention FS. dislocation after total hip - 1 arthroplasty. Arthroplasty. 2018;33:1316-24, http://dx.doi.org/10.1016/j.arth.2018.01.047.
- 16. Dargel J, Oppermann J. Brüggemann GP. Evsel P. Dislocation following total hip replacement. Dtsch Arztebl Int. 2014;111:884-90, http://dx.doi.org/10.3238/arztebl.2014.0884.
- Renard G, Laffosse JM, Tibbo M, Lucena T, Cavaignac E, Rouvillain JL, et al. Periprosthetic joint infection in aseptic total hip arthroplasty revision. Int Orthop. 2020;44, http://dx.doi.org/10.1007/s00264-019-04366-2.
- Ahmed SS, Begum F, Kayani B, Haddad FS. Risk factors, diagnosis and management of prosthetic joint infection after total hip arthroplasty. Expert Rev Med Devices. 2019;16:1063–70, http://dx.doi.org/10.1080/17434440.2019.1696673.
- Franceschini M, Sandiford NA, Cerbone V, Araujo LCT, Kendoff D. Defensive antibacterial coating in revision total hip arthroplasty: new concept and early experience. Hip Int. 2020;30 1_suppl:7-11, http://dx.doi.org/10.1177/1120700020917125.
- Papagrigorakis E, Galanis A, Vlachos C, Vavourakis M, Zachariou D, Vlamis J, et al. Periprosthetic fracture of total hip replacement in patients with osteopetrosis: a case presentation and review of literature. J Frailty Sarcopenia Falls. 2022;7:251-6, http://dx.doi.org/10.22540/JFSF-07-251.
- 21. Hasija R, Kelly JJ, Shah NV, Newman JM, Chan JJ, Robinson J, et al. Nerve injuries associated with total hip arthroplasty. J Clin Orthop Trauma. 2018;9:81–6, http://dx.doi.org/10.1016/j.jcot.2017.10.011.

- Zeng C, Lane NE, Englund M, Xie D, Chen H, Zhang Y, et al. In-hospital mortality after hip arthroplasty in China: analysis of a large national database. Bone Joint J. 2019;101B:1209–17, http://dx.doi.org/10.1302/0301-620X.101B10.BJJ-2018-1608.R1.
- 23. Edwards PK, Mears SC, Stambough JB, Foster SE, Barnes CL. Choices, compromises, and controversies in total knee and total hip arthroplasty modifiable risk factors: what you need to know. J Arthroplasty. 2018;33:3101–6, http://dx.doi.org/10.1016/j.arth.2018.02.066.
- 24. Podmore B, Hutchings A, Skinner JA, MacGregor AJ, van der Meulen J. Impact of comorbidities on the safety and effectiveness of hip and knee arthroplasty surgery. Bone Joint J. 2021;103B:56-64, http://dx.doj.org/10.1302/0301-620X.103B1.BJJ-2020-0859.R1.
- 25. Singh JA, Sloan J. Higher comorbidity, poor functional status and higher health care utilization in veterans with prevalent total knee arthroplasty or total hip arthroplasty. Clin Rheumatol. 2009;28:1025–33, http://dx.doi.org/10.1007/s10067-009-1201-4.
- 26. Stibolt RD Jr, Patel HA, Huntley SR, Lehtonen EJ, Shah AB, Naranje SM. Total hip arthroplasty for posttraumatic osteoarthritis following acetabular fracture: a systematic review of characteristics, outcomes, and complications. Chin J Traumatol. 2018;21:176–81, http://dx.doi.org/10.1016/j.cjtee.2018.02.004.
- 27. Patil A, Sephton BM, Ashdown T, Bakhshayesh P. Blood loss and transfusion rates following total hip arthroplasty: a multivariate analysis. Acta Orthop Belg. 2022;88:27–34, http://dx.doi.org/10.52628/88.1.04.
- 28. Sizer SC, Cherian JJ, Elmallah RD, Pierce TP, Beaver WB, Mont MA. Predicting blood loss in total knee and hip arthroplasty. Orthop Clin North Am. 2015;46:445–59, http://dx.doi.org/10.1016/j.ocl.2015.06.002.